Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.

Illumina said adding SomaLogic would support the company’s multiomics strategy and strengthen the value of its NovaSeq X ...

Illumina (NASDAQ:ILMN) has unveiled new artificial intelligence software, PrimateAI-3D, that can predict disease-causing genetic mutations in individuals. The genetic analysis and sequencing ...

The sequencing results are being made freely available to the scientific community. News DNA Gene mutation Genome sequencing Human genome Element Biosciences Illumina Oxford Nanopore PacBio Share ...

“If I get 10 samples of one mutation from 10 different patients, they’re all going to have different genetic backgrounds; they may behave differently. We’re trying to use the sequencing power that ...

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO, May 29, 2025 /PRNewswire ...

Next Generation Sequencing (NGS) is a relatively new technique for sequencing nucleic acids and detecting genomic mutations. 1 This technology is based on the advantages of sequencing chemistries ...

Illumina is the only sequencing company that provides all the components to do WGS heme testing across library prep, sequencing, secondary analysis, and interpretation. The DRAGEN heme solution is ...

Illumina inked a deal with Standard BioTools to acquire SomaLogic for $350 million in cash. The maker of gene-sequencing equipment and services said Monday that the deal includes an additional payout ...

SAN DIEGO, June 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the new PrimateAI-3D, an artificial ...

With PromoterAI applied to whole-genome sequencing (WGS) ... a deep learning tool for interpreting noncoding cryptic splice mutations. In 2023, Illumina released PrimateAI-3D, ...